Week in Review: China Life Science Posts $1.3 Billion in Deals

Deals and Financings   Pacific Biosciences will acquire Omniome in an $800 million deal that joins US sequencing companies; Shanghai 's Decheng is a major Omniome backer; Shanghai 's Zai Lab will pay up to $338 million in a collaboration with Schrödinger to develop a novel oncology product targeting DNA damage; Berry Oncology completed a $99 million Series B round to support its portfolio of genomic testing products and services for oncology; Shanghai Zentera Therapeutics raised $75 million in a Series B financing to support clinical development of its three main cancer drug candidates; Engrail Therapeutics, a  San Diego  neuroscience company, closed a $32 million extension of its Series A financing from Nan Fung Life Sciences of Hong Kong; Shanghai Promega will collaborate with Shanghai Henlius Biotech to provide a companion IVD kit for Henlius' serplulimab, its anti-PD-1 drug;  Trials and Approvals   Akeso and Sino Bio were approved to launch their partnered anti-PD-1 injection in  China  for classic Hodgkin's lymphoma; BeyondSpring, a New York-China pharma, reported its lead asset, plinabulin, posted positive topline data in a US Phase III trial among NSCLC patients; Shenzhen ImmVira was approved start a Phase I trial of its lead intravenous oncolytic virus therapy in  China ; Suzhou 's Transcenta was granted Orphan Drug Designation in the  US  for its anti-Claudin18.2 mAb in patients with gastric cancers; ASO Bio, a  Nanjing  biotech, was approved to start clinical trials of its autologous CD19/CD22 CAR-T therapy for two indications.   Stock Symbols: (NSDQ: PACB) (NSDQ: ZLAB; HKEX: 9688) (NSDQ: SDGR) (HK: 2696) (HK: 1177) (HK: 9926) (NSDQ: BYSI) Share this with colleagues: // //